Importantly, MGMT promoter methylation serves as a clinically significant predictive biomarker in the treatment planning of elderly glioblastoma patients, guiding therapeutic decisions and predicting response to TMZ-based therapy. This evidence concerns the gene MGMT and glioblastoma.